Next 10 |
2024-05-09 17:36:13 ET More on Viracta Therapeutics Day One wins FDA nod for brain cancer therapy, Ojemda Viracta slides on lower response rate in trial for lymphoma treatment cohort Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earni...
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate ...
2024-04-23 13:59:37 ET More on Day One Biopharma, Viracta, etc. Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects Viracta slides on lower response rate in trial for lymphoma treatment cohort Xoma to acquire Kinnate Biopharma for $2.3352 -...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 5.1% to $11.44 on volume of 198,678,404 shares Trio Petroleum Corp. (TPET) rose 22.1% to $0.63 on volume of 179,140,668 shares Soligenix Inc. (SNGX) rose 21.7% to $0.47 on volume of 133,754,026 shares Sup...
2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
2024-04-15 08:40:27 ET More on Viracta Therapeutics Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Financial information for Viracta Therapeutics Read the full article on Seeking Alpha For...
2024-04-15 08:21:07 ET More on Pre-market losers & stocks. OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable populati...
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate ...
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers repo...